SAFETY DATA SHEET

Embutramide / Mebezonium / Tetracaine Formulation

Version 4.1  Revision Date: 04/04/2023
SDS Number: 1714262-00020  Date of last issue: 01/20/2023
Date of first issue: 05/25/2017

SECTION 1. IDENTIFICATION

Product name: Embutramide / Mebezonium / Tetracaine Formulation
Other means of identification: No data available

Manufacturer or supplier’s details
Company name of supplier: Merck & Co., Inc
Address: 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065
Telephone: 908-740-4000
Emergency telephone: 1-908-423-6000
E-mail address: EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use
Recommended use: Veterinary product
Restrictions on use: Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations
Flammable liquids: Category 4
Acute toxicity (Oral): Category 4
Acute toxicity (Inhalation): Category 4
Acute toxicity (Dermal): Category 4
Eye irritation: Category 2A
Reproductive toxicity: Category 1B
Specific target organ toxicity - single exposure: Category 2 (Nervous system, muscle)
Specific target organ toxicity - single exposure: Category 3

GHS label elements
Hazard pictograms:

Signal Word: Danger
Hazard Statements: H227 Combustible liquid.
H302 + H312 + H332 Harmful if swallowed, in contact with skin or if inhaled.
SAFETY DATA SHEET

Embutramide / Mebezonium / Tetracaine Formulation

Precautionary Statements:

Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P210 Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking.
P260 Do not breathe mist or vapors.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P271 Use only outdoors or in a well-ventilated area.
P280 Wear protective gloves, protective clothing, eye protection and face protection.

Response:
P301 + P312 + P330 IF SWALLOWED: Call a doctor if you feel unwell. Rinse mouth.
P302 + P352 + P312 IF ON SKIN: Wash with plenty of soap and water. Call a doctor if you feel unwell.
P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a doctor if you feel unwell.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P311 IF exposed or concerned: Call a doctor.
P337 + P313 IF eye irritation persists: Get medical attention.
P362 + P364 Take off contaminated clothing and wash it before reuse.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards:
Vapors may form explosive mixture with air.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Mixture</th>
</tr>
</thead>
</table>

**Components**

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>Common Name/Synonym</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>N,N-Dimethylformamide</td>
<td>Formic acid dimethylamide</td>
<td>68-12-2</td>
<td>&gt;= 30 - &lt; 60 *</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET

Embutramide / Mebezonium / Tetracaine Formulation

Version 4.1
Revision Date: 04/04/2023
SDS Number: 1714262-00020
Date of last issue: 01/20/2023
Date of first issue: 05/25/2017

<table>
<thead>
<tr>
<th>Substance</th>
<th>Concentration Range</th>
<th>SDS Number</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Embutramide</td>
<td>No data available</td>
<td>15687-14-6</td>
<td></td>
</tr>
<tr>
<td>Mebezonium iodide</td>
<td>No data available</td>
<td>7681-78-9</td>
<td></td>
</tr>
<tr>
<td>Tetracaine hydrochloride</td>
<td>No data available</td>
<td>136-47-0</td>
<td></td>
</tr>
</tbody>
</table>

* Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and delayed: Harmful if swallowed, in contact with skin or if inhaled. Causes serious eye irritation. May cause drowsiness or dizziness. May damage the unborn child. May cause damage to organs.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: High volume water jet

Specific hazards during fire fighting: Do not use a solid water stream as it may scatter and spread fire. Flash back possible over considerable distance.
**SAFETY DATA SHEET**

**Embutramide / Mebezonium / Tetracaine Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1</td>
<td>04/04/2023</td>
<td>1714262-00020</td>
<td>01/20/2023</td>
<td>05/25/2017</td>
</tr>
</tbody>
</table>

**Hazardous combustion products**: Carbon oxides
Nitrogen oxides (NOx)

**Specific extinguishing methods**: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

**Special protective equipment for fire-fighters**: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

### SECTION 6. ACCIDENTAL RELEASE MEASURES

**Personal precautions, protective equipment and emergency procedures**: Remove all sources of ignition. Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

**Environmental precautions**: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

**Methods and materials for containment and cleaning up**: Non-sparking tools should be used. Soak up with inert absorbent material. Suppress (knock down) gases/vapors/mists with a water spray jet. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

**Technical measures**: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

**Local/Total ventilation**: If sufficient ventilation is unavailable, use with local exhaust ventilation.
SAFETY DATA SHEET

Embutramide / Mebezonium / Tetracaine Formulation

Version: 4.1  Revision Date: 04/04/2023  SDS Number: 1714262-00020  Date of last issue: 01/20/2023  Date of first issue: 05/25/2017

Advice on safe handling:
- Do not get on skin or clothing.
- Do not breathe mist or vapors.
- Do not swallow.
- Do not get in eyes.
- Wash skin thoroughly after handling.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Keep container tightly closed.
- Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking.
- Take precautionary measures against static discharges.
- Do not eat, drink or smoke when using this product.
- Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage:
- Keep in properly labeled containers.
- Store locked up.
- Keep tightly closed.
- Keep in a cool, well-ventilated place.
- Store in accordance with the particular national regulations.
- Keep away from heat and sources of ignition.

Materials to avoid:
- Do not store with the following product types:
  - Strong oxidizing agents
  - Self-reactive substances and mixtures
  - Organic peroxides
  - Explosives
  - Gases

SECTION 8. EXPOSURE CONTROLS/PERSOMAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>N,N-Dimethylformamide</td>
<td>68-12-2</td>
<td>TWA</td>
<td>10 ppm&lt;br&gt;30 mg/m³</td>
<td>CA AB OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>5 ppm&lt;br&gt;30 mg/m³</td>
<td>CA BC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA EV</td>
<td>10 ppm&lt;br&gt;30 mg/m³</td>
<td>CA QC OEL</td>
</tr>
<tr>
<td>Embutramide</td>
<td>15687-14-6</td>
<td>TWA</td>
<td>10 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>STEL</td>
<td>30 µg/m³</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>100 µg/100 cm²</td>
<td>Internal</td>
</tr>
<tr>
<td>Mebezonium iodide</td>
<td>7681-78-9</td>
<td>TWA</td>
<td>1 µg/m³ (OEB 4)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>STEL</td>
<td>3 µg/m³ (OEB 4)</td>
<td>Internal</td>
</tr>
<tr>
<td>Tetracaine hydrochloride</td>
<td>136-47-0</td>
<td>TWA</td>
<td>5 µg/m³ (OEB 4)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>50 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Further information: DSEN, Skin
Biological occupational exposure limits

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Control parameters</th>
<th>Biological specimen</th>
<th>Sampling time</th>
<th>Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>N,N-Dimethylformamide</td>
<td>68-12-2</td>
<td>Total N-Methylformamide</td>
<td>Urine</td>
<td>End of shift (As soon as possible after exposure ceases)</td>
<td>30 mg/l</td>
<td>ACGIH BEI</td>
</tr>
<tr>
<td>N-Acetyl-S-(N-methylcarbamoyl)cysteine</td>
<td></td>
<td></td>
<td>Urine</td>
<td>End of shift at end of work-week</td>
<td>30 mg/l</td>
<td>ACGIH BEI</td>
</tr>
</tbody>
</table>

Engineering measures:
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted. Use closed processing systems or containment technologies. If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipment

Respiratory protection:
If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type:
Combined particulates, ammonia/amines and organic vapor type

Hand protection

Material:
Chemical-resistant gloves

Remarks:
Consider double gloving. Take note that the product is flammable, which may impact the selection of hand protection.

Eye protection:
Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection:
Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures:
If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the
SAFETY DATA SHEET

Embutramide / Mebezonium / Tetracaine Formulation

Version 4.1 Revision Date: 04/04/2023 SDS Number: 1714262-00020 Date of last issue: 01/20/2023 Date of first issue: 05/25/2017

Working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate de-gowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>liquid</td>
</tr>
<tr>
<td>Color</td>
<td>No data available</td>
</tr>
<tr>
<td>Odor</td>
<td>No data available</td>
</tr>
<tr>
<td>Odor Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>5 - 6</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>81 °C</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapor pressure</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative vapor density</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative density</td>
<td>No data available</td>
</tr>
<tr>
<td>Density</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td></td>
</tr>
<tr>
<td>Water solubility</td>
<td>soluble</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>No data available</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET

Embutramide / Mebezonium / Tetracaine Formulation

Version 4.1  Revision Date: 04/04/2023  SDS Number: 1714262-00020  Date of last issue: 01/20/2023  Date of first issue: 05/25/2017

Autoignition temperature : No data available
Decomposition temperature : No data available
Viscosity
  Viscosity, kinematic : No data available
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Molecular weight : Not applicable
Particle size : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions
  Vapors may form explosive mixture with air. Can react with strong oxidizing agents.
Conditions to avoid : Heat, flames and sparks.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Harmful if swallowed, in contact with skin or if inhaled.

Product:
Acute oral toxicity : Acute toxicity estimate: 1,224 mg/kg
  Method: Calculation method
Acute inhalation toxicity : Acute toxicity estimate: 19.41 mg/l
  Exposure time: 4 h
  Test atmosphere: vapor
  Method: Calculation method
Acute dermal toxicity : Acute toxicity estimate: 1,942 mg/kg
  Method: Calculation method
Components:

**N,N-Dimethylformamide:**
Acute oral toxicity : LD50 (Rat): 3,010 mg/kg
Acute inhalation toxicity :
  - Acute toxicity estimate: 11 mg/l
  - Exposure time: 4 h
  - Test atmosphere: vapor
  - Method: Expert judgment
  - Remarks: Based on national or regional regulation.
Acute dermal toxicity :
  - Acute toxicity estimate: 1,100 mg/kg
  - Method: Expert judgment
  - Remarks: Based on national or regional regulation.

**Embutramide:**
Acute oral toxicity : LD50 (Rat): 1,550 mg/kg
Acute toxicity (other routes of administration) :
  - LD50 (Dog): 31 mg/kg
  - Application Route: Intravenous
  - TDLo (Dog): 15.5 mg/kg
  - Application Route: Intravenous
  - Symptoms: narcosis
  - LD50 (Horse): 20 mg/kg
  - Application Route: Intravenous
  - LD50 (Sheep): 80 mg/kg
  - Application Route: Intravenous
  - LD50 (Pig): 100 mg/kg
  - Application Route: Intravenous

**Mebezonium iodide:**
Acute oral toxicity :
  - LD50 (Rat, female): 200 - 300 mg/kg
Acute toxicity (other routes of administration) :
  - LC50 (Dog): 15 mg/kg
  - Application Route: Intravenous

**tetracaine hydrochloride:**
Acute toxicity (other routes of administration) :
  - LD50 (Rat): 6 mg/kg
  - Application Route: Intravenous
  - LD50 (Mouse): 6 mg/kg
  - Application Route: Intravenous

**Skin corrosion/irritation**
Not classified based on available information.
Components:

N,N-Dimethylformamide:
Species: Rabbit
Result: No skin irritation

Serious eye damage/eye irritation
Causes serious eye irritation.

Components:

N,N-Dimethylformamide:
Species: Rabbit
Result: Irritation to eyes, reversing within 21 days

Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
Not classified based on available information.

Components:

N,N-Dimethylformamide:
Test Type: Local lymph node assay (LLNA)
Routes of exposure: Skin contact
Species: Mouse
Result: negative
tetracaine hydrochloride:
Routes of exposure: Dermal
Result: Sensitizer

Germ cell mutagenicity
Not classified based on available information.

Components:

N,N-Dimethylformamide:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
SAFETY DATA SHEET

Embutramide / Mebezonium / Tetracaine Formulation

Genotoxicity in vivo:
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  - Species: Mouse
  - Application Route: Intraperitoneal injection
  - Result: negative

- Test Type: Rodent dominant lethal test (germ cell) (in vivo)
  - Species: Rat
  - Application Route: Inhalation (vapor)
  - Result: negative

- Test Type: Rodent dominant lethal test (germ cell) (in vivo)
  - Species: Mouse
  - Application Route: Intraperitoneal injection
  - Result: negative

Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative

- Test Type: Chromosomal aberration
  - Result: equivocal

Carcinogenicity
Not classified based on available information.

Components:

N,N-Dimethylformamide:
- Species: Rat
- Application Route: Inhalation (vapor)
- Exposure time: 2 Years
- Method: OECD Test Guideline 451
- Result: negative

- Species: Mouse
- Application Route: Inhalation (vapor)
- Exposure time: 18 Months
- Method: OECD Test Guideline 451
- Result: negative

Reproductive toxicity
May damage the unborn child.

Components:

N,N-Dimethylformamide:
## Embutramide / Mebezonium / Tetracaine Formulation

### Effects on fertility

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Species</th>
<th>Application Route</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Two-generation study</td>
<td>Mouse</td>
<td>Ingestion</td>
<td>negative</td>
</tr>
<tr>
<td>One-generation reproduction toxicity study</td>
<td>Rat</td>
<td>Skin contact</td>
<td>negative</td>
</tr>
</tbody>
</table>

### Effects on fetal development

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Species</th>
<th>Application Route</th>
<th>Method</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Embryo-fetal development</td>
<td>Rabbit</td>
<td>Inhalation (vapor)</td>
<td>OECD Test Guideline 414</td>
<td>positive</td>
</tr>
<tr>
<td>Embryo-fetal development</td>
<td>Rabbit</td>
<td>Skin contact</td>
<td>OECD Test Guideline 414</td>
<td>positive</td>
</tr>
</tbody>
</table>

### Reproductive toxicity - Assessment

- Clear evidence of adverse effects on development, based on animal experiments.

### Tetracaine hydrochloride:

#### Effects on fertility

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Species</th>
<th>Application Route</th>
<th>Fertility: NOAEL</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fertility</td>
<td>Rat, male and female</td>
<td>Subcutaneous</td>
<td>7.5 mg/kg body weight</td>
<td>No effects on fertility</td>
</tr>
</tbody>
</table>

#### Effects on fetal development

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Species</th>
<th>Application Route</th>
<th>Developmental Toxicity: NOAEL</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Development</td>
<td>Rat</td>
<td>Subcutaneous</td>
<td>5 mg/kg body weight</td>
<td>No teratogenic effects</td>
</tr>
<tr>
<td>Development</td>
<td>Rabbit</td>
<td>Subcutaneous</td>
<td>10 mg/kg body weight</td>
<td>No teratogenic effects</td>
</tr>
</tbody>
</table>

### STOT-single exposure

- May cause drowsiness or dizziness.
- May cause damage to organs (Nervous system, muscle).

### Components:

#### Embutramide:

| Assessment | May cause drowsiness or dizziness. |
Mebezonium iodide:
Target Organs: Nervous system, muscle
Assessment: May cause damage to organs.

tetracaine hydrochloride:
Target Organs: Central nervous system, Cardio-vascular system
Assessment: Causes damage to organs.

STOT-repeated exposure
Not classified based on available information.

Repeated dose toxicity

Components:

N,N-Dimethylformamide:
Species: Rat
NOAEL: 238 mg/kg
LOAEL: 475 mg/kg
Application Route: Ingestion
Exposure time: 28 Days

Species: Rat
NOAEL: 0.08 mg/l
LOAEL: 0.3 mg/l
Application Route: inhalation (vapor)
Exposure time: 2 y

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Embutraamide:
Inhalation: Target Organs: Central nervous system
Symptoms: Drowsiness, Central nervous system depression, muscle weakness, Shortness of breath

Mebezonium iodide:
Inhalation: Symptoms: Weakness, Fatigue, Breathing difficulties

tetracaine hydrochloride:
Inhalation: Target Organs: Cardio-vascular system
Target Organs: Central nervous system
Symptoms: Central nervous system depression, Dizziness, Headache, hypotension, Vomiting

Skin contact: Symptoms: Redness, pruritis
SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

N,N-Dimethylformamide:
Toxicity to fish: LC50 (Lepomis macrochirus (Bluegill sunfish)): 7,100 mg/l
Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 13,100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants:
- ErC50 (Desmodesmus subspicatus (green algae)): > 1,000 mg/l
  Exposure time: 72 h
- EC10 (Desmodesmus subspicatus (green algae)): > 1,000 mg/l
  Exposure time: 72 h
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
- NOEC (Daphnia magna (Water flea)): 1,500 mg/l
  Exposure time: 21 d

Embutramide:
Toxicity to fish: LC50: 21 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Toxicity to microorganisms:
- EC50: > 1,000 mg/l
  Exposure time: 24 h
  Test Type: Respiration inhibition of activated sludge
  Method: OECD Test Guideline 209

Persistence and degradability

Components:

N,N-Dimethylformamide:
Biodegradability: Result: Readily biodegradable.
Biodegradation: 100 %
Exposure time: 21 d
Method: OECD Test Guideline 301E

Bioaccumulative potential

Components:

N,N-Dimethylformamide:
Bioaccumulation: Species: Cyprinus carpio (Carp)
Bioconcentration factor (BCF): 0.3 - 1.2
Method: OECD Test Guideline 305C

Partition coefficient: n-octanol/water : log Pow: -0.93
Remarks: Calculation

Mobility in soil
No data available

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues : Dispose of in accordance with local regulations.
Do not dispose of waste into sewer.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
Empty containers retain residue and can be dangerous.
Do not pressurize, cut, weld, braze, solder, drill, grind, or expose such containers to heat, flame, sparks, or other sources of ignition. They may explode and cause injury and/or death.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations
UNRTDG
Not regulated as a dangerous good
IATA-DGR
Not regulated as a dangerous good
IMDG-Code
Not regulated as a dangerous good
Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation
TDG
Not regulated as a dangerous good

Special precautions for user
Not applicable

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:
AICS : not determined
# SAFETY DATA SHEET

**Embutramide / Mebezonium / Tetracaine Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1</td>
<td>04/04/2023</td>
<td>1714262-00020</td>
<td>01/20/2023</td>
<td>05/25/2017</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DSL</th>
<th>not determined</th>
</tr>
</thead>
<tbody>
<tr>
<td>IECSC</td>
<td>not determined</td>
</tr>
</tbody>
</table>

## SECTION 16. OTHER INFORMATION

**Full text of other abbreviations**

- **ACGIH**: USA. ACGIH Threshold Limit Values (TLV)
- **ACGIH BEI**: ACGIH - Biological Exposure Indices (BEI)
- **CA AB OEL**: Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)
- **CA BC OEL**: Canada. British Columbia OEL
- **CA QC OEL**: Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for airborne contaminants
- **ACGIH / TWA**: 8-hour, time-weighted average
- **CA BC OEL / TWA**: 8-hour Occupational exposure limit
- **CA BC OEL / TWA**: 8-hour time weighted average
- **CA QC OEL / TWAEV**: Time-weighted average exposure value

**Abbreviations**

- AIIC - Australian Inventory of Industrial Chemicals
- ANTT - National Agency for Transport by Land of Brazil
- ASTM - American Society for the Testing of Materials
- bw - Body weight
- CMR - Carcinogen, Mutagen or Reproductive Toxicant
- DIN - Standard of the German Institute for Standardisation
- DSL - Domestic Substances List (Canada)
- ECx - Concentration associated with x% response
- ELx - Loading rate associated with x% response
- EmS - Emergency Schedule
- ENCS - Existing and New Chemical Substances (Japan)
- ErCx - Concentration associated with x% growth rate response
- ERG - Emergency Response Guide
- GHS - Globally Harmonized System
- GLP - Good Laboratory Practice
- IARC - International Agency for Research on Cancer
- IATA - International Air Transport Association
- IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk
- IC50 - Half maximal inhibitory concentration
- ICAO - International Civil Aviation Organization
- IECSC - Inventory of Existing Chemical Substances in China
- IMDG - International Maritime Dangerous Goods
- IMO - International Maritime Organization
- ISHL - Industrial Safety and Health Law (Japan)
- ISO - International Organisation for Standardization
- KECl - Korea Existing Chemicals Inventory
- LC50 - Lethal Concentration to 50% of a test population
- LD50 - Lethal Dose to 50% of a test population
- MARPOL - International Convention for the Prevention of Pollution from Ships
- n.o.s. - Not Otherwise Specified
- Nch - Chilean Norm
- NO(A)EC - No Observed (Adverse) Effect Concentration
- NO(A)EL - No Observed (Adverse) Effect Level
- NOELR - No Observable Effect Loading Rate
- NOM - Official Mexican Norm
- NTP - National Toxicology Program
- NZIoC - New Zealand Inventory of Chemicals
- OECD - Organization for Economic Co-operation and Development
- OPPTS - Office of Chemical Safety and Pollution Prevention
- PBT - Persistent, Bioaccumulative and Toxic substance
- PICCS - Philippines Inventory of Chemicals and Chemical Substances
- (Q)SAR - (Quantitative) Structure Activity Relationship
- SAC - Self-Accelerating Decomposition Temperature
- SDS - Safety Data Sheet
- TCSI - Taiwan Chemical Substance Inventory
- TDG - Transportation of Dangerous Goods
- TECI - Toxic Substances Control Act (United States)
- UN - United Nations
- UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods
- vPvB - Very Persistent and Very Bioaccumulative
- WHMIS - Workplace Hazardous Materials Information System
SAFETY DATA SHEET

Embutramide / Mebezonium / Tetracaine Formulation

Version 4.1  Revision Date: 04/04/2023  SDS Number: 1714262-00020  Date of last issue: 01/20/2023

Date of first issue: 05/25/2017

Sources of key data used to compile the Material Safety Data Sheet:

Revision Date: 04/04/2023
Date format: mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

CA / Z8